Premium
Immunoregulatory functions of VISTA
Author(s) -
Nowak Elizabeth C.,
Lines J. Louise,
Varn Frederick S.,
Deng Jie,
Sarde Aurelien,
Mabaera Rodwell,
Kuta Anna,
Le Mercier Isabelle,
Cheng Chao,
Noelle Randolph J.
Publication year - 2017
Publication title -
immunological reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.839
H-Index - 223
eISSN - 1600-065X
pISSN - 0105-2896
DOI - 10.1111/imr.12525
Subject(s) - immunotherapy , context (archaeology) , cancer immunotherapy , computational biology , clinical trial , biology , cancer , immunology , medicine , bioinformatics , oncology , immune system , genetics , paleontology
Summary Utilization of negative checkpoint regulators ( NCR s) for cancer immunotherapy has garnered significant interest with the completion of clinical trials demonstrating efficacy. While the results of monotherapy treatments are compelling, there is increasing emphasis on combination treatments in an effort to increase response rates to treatment. One of the most recently discovered NCR s is VISTA (V‐domain Ig‐containing Suppressor of T cell Activation). In this review, we describe the functions of this molecule in the context of cancer immunotherapy. We also discuss factors that may influence the use of anti‐ VISTA antibody in combination therapy and how genomic analysis may assist in providing indications for treatment.